Nuvalent (NASDAQ:NUVL) Insider Sells $76,888.00 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $109.84, for a total transaction of $76,888.00. Following the completion of the transaction, the insider directly owned 59,634 shares in the company, valued at $6,550,198.56. This trade represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Deborah Ann Miller also recently made the following trade(s):

• On Thursday, January 22nd, Deborah Ann Miller sold 14,300 shares of Nuvalent stock. The shares were sold at an average price of $110.16, for a total value of $1,575,288.00.
• On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total value of $251,547.24.
• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total value of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The stock was sold at an average price of $103.16, for a total value of $2,248,888.00.

Nuvalent Trading Down 5.0%

Shares of NUVL stock opened at $106.44 on Monday. Nuvalent, Inc. has a twelve month low of $55.53 and a twelve month high of $113.01. The company’s 50-day moving average price is $105.12 and its 200-day moving average price is $91.22. The stock has a market cap of $7.74 billion, a price-to-earnings ratio of -20.01 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same period in the previous year, the business posted ($1.28) EPS. As a group, equities research analysts predict that Nuvalent, Inc. will post -3.86 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NUVL. AQR Capital Management LLC raised its position in Nuvalent by 64.8% in the 1st quarter. AQR Capital Management LLC now owns 9,874 shares of the company’s stock valued at $700,000 after purchasing an additional 3,881 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Nuvalent by 54.4% in the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company’s stock valued at $32,171,000 after purchasing an additional 159,873 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Nuvalent by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company’s stock valued at $10,634,000 after purchasing an additional 12,123 shares during the last quarter. Intech Investment Management LLC raised its holdings in Nuvalent by 28.7% during the first quarter. Intech Investment Management LLC now owns 19,262 shares of the company’s stock worth $1,366,000 after purchasing an additional 4,293 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Nuvalent by 9,230.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock worth $93,000 after buying an additional 1,200 shares during the last quarter. 97.26% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. The Goldman Sachs Group increased their price objective on Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Leerink Partners lifted their price target on shares of Nuvalent from $140.00 to $149.00 and gave the company an “outperform” rating in a research report on Monday, November 17th. Canaccord Genuity Group initiated coverage on shares of Nuvalent in a research note on Wednesday, November 12th. They issued a “buy” rating and a $126.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Nuvalent in a report on Wednesday, October 15th. They issued an “overweight” rating and a $135.00 target price for the company. Finally, UBS Group reaffirmed a “buy” rating on shares of Nuvalent in a research note on Wednesday, December 17th. Fifteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.33.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.